Muutke küpsiste eelistusi

E-raamat: Trends on the Role of Pet in Drug Development [World Scientific e-raamat]

Edited by (Univ Medical Center Groningen, The Netherlands), Edited by (Univ Medical Center Groningen, The Netherlands), Edited by (Univ Medical Center Groningen, The Netherlands), Edited by (Univ Medical Center Groningen, The Netherlands)
  • Formaat: 800 pages, Illustrations
  • Ilmumisaeg: 01-Mar-2012
  • Kirjastus: World Scientific Publishing Co Pte Ltd
  • ISBN-13: 9789814317740
Teised raamatud teemal:
  • World Scientific e-raamat
  • Hind: 255,02 €*
  • * hind, mis tagab piiramatu üheaegsete kasutajate arvuga ligipääsu piiramatuks ajaks
Trends on the Role of Pet in Drug DevelopmentSuurem pilt
  • Formaat: 800 pages, Illustrations
  • Ilmumisaeg: 01-Mar-2012
  • Kirjastus: World Scientific Publishing Co Pte Ltd
  • ISBN-13: 9789814317740
Teised raamatud teemal:
World Scientific e-raamatudRohkem infot World Scientific e-raamatute kohta
Raamatu kodulehekülg: http://www.worldscientific.com/worldscibooks/10.1142/7851#t=toc
Drug development is very expensive and a fight against time. PET offers possibilities to speed up this process by adding unique in vivo information on pharmacokinetics/dynamics of a drug at an early stage. This information can help decision makers to move the drug in the drug development process or to decide to stop further developments. This unique and complete book highlights the different ways PET can be used and describes the latest trends in the various disciplines within nuclear medicine to further improve methodologies and increase the number of tools to accelerate drug development. Various topics within tracer development, instrumentation, data analysis and many clinical and preclinical topics are described by leading scientists from industry and academia.
The Editors ix
Contributors xiii
Preface xxvii
1 Introduction on PET. Description of Basics and Principles
1(14)
Aren van Waarde
2 Drug Development in the Pharmaceutical Industry
15(18)
Adrian D. Nunn
3 Molecular Imaging Biomarkers as a Tool in Development of Novel Medicines
33(16)
R. Paul Maguire
4 What is the Role of Positron Emission Tomography in Drug Development?
49(20)
Timothy J. McCarthy
5 Review of 11C Preparations and Examples in Drug Development
69(42)
Farhad Karimi
Bengt Langstrom
6 The Role of Recent Development of 18F Radiochemistry in Drug Development
111(70)
Farhad Karimi
Bengt Langstrom
7 The Synthesis and Design of Radiotracers for Positron Emission Tomography
181(12)
Antony D. Gee
8 Overview of Animal Models of Cancer, Neurodegenerative Disease and Inflammation
193(26)
Jun Toyohara
Kiichi Ishiwata
9 Small Animal Imaging for Accelerating Drug Development, and Comparison to Other Techniques
219(22)
Aage Kristian Olsen Alstrup
10 Animal PET Research with Non-Human Primates for Drug Development in Pre-Clinical Stage --- The Hamamatsu Experience
241(20)
Hideo Tsukada
11 Clinical PET Technology
261(28)
Yves D'Asseler
Christophe Van de Wiele
12 Small Animal PET Cameras --- Development, Technology, PET/CT, PET/MRI
289(30)
Julia G. Mannheim
Hans F. Wehrl
Martin S. Judenhofer
Bernd J. Pichler
13 Multimodality Imaging: Overview of Imaging Techniques (CT, MRI, PET, Optical Imaging) and Impact of Multimodality Imaging on Drug Development
319(64)
Yannic Waerzeggers
Parisa Monfared
Roland Ullrich
Thomas Viel
Andreas H. Jacobs
14 The Cyclotron Production of Short-Lived Positron Emitting Radionuclides
383(34)
Roel Wierts
Rudi A. J. O. Dierckx
Anne M. J. Paans
15 An Introduction to Kinetic Modeling and Quantification and its Role in Drug Development
417(38)
Antoon T. M. Willemsen
Anne M. J. Paans
16 Clinical Application of PET Imaging in the Lungs for Drug Development
455(22)
Delphine L. Chen
17 Radiolabeled Drugs or the Use of Surrogate Biomarkers to Evaluate New Anticancer-Agents
477(30)
Uwe Haberkorn
18 PET Imaging of the Cardiovascular System in Drug Development: Status and Vision
507(28)
Michael Schafers
19 Psychiatry --- Relevance with Respect to Drug Development, Examples
535(24)
Khanum Ridler
Marc Laruelle
Eugenii A. Rabiner
20 The Role of PET in Drug Discovery --- Neuropsychiatry
559(16)
Andreas Otte
21 The Impact of the BBB on the Pharmacokinetics of Drugs: Investigations by PET
575(40)
Jashvant D. Unadkat
Ban Ke
Sara Eyal
22 The Role of Contract Research Organizations (CROs) in Imaging for the Drug Development Process
615(14)
Izaak den Daas
Thijs van Iersel
Johan Wemer
23 The Role of Nuclear Medicine in Inflammatory Diseases: Drug Targets and Clinical Applications
629(52)
Andor W. J. M. Glaudemans
Erik F. J. de Vries
Marco Chianelli
Tiziana Lanzolla
Rudi A. J. O. Dierckx
Alberto Signore
24 Molecular Imaging of the Receptor HER2 and the Ligand VEGF as Role Models for the Use of ImmunoPET in Drug Development
681(10)
Sietske B. M. Gaykema
Elisabeth G. E. de Vries
Thijs H. Oude Munnink
Wouter B. Nagengast
Anton G. T. Terwisscha van Scheltinga
Geke A. P. Hospers
Rudi A. J. O. Dierckx
Adrienne H. Brouwers
Carolina P. Schroder
Marjolijn N. Lub-de Hooge
25 Good Clinical Practice and Nuclear Medicine
691(36)
Andor W. J. M. Glaudemans
Rudi A. J. O Dierckx
Andreas Otte
Zvonko Kusic
Jan Pruim
Peter P. De Deyn
26 Basic Aspects of Good Manufacturing Practice for PET-Radiopharmaceuticals
727(24)
Hendrikus H. Boersma
Marieke G. G. Sturkenboom
Marjolijn N. Lub-de Hooge
Philip H. Elsinga
Gert Luurtsema
Rudi A. J. O. Dierckx
Jos G. W. Kosterink
Epilog 751(12)
Philip H. Elsinga
Aren van Waarde
Anne M. J. Paans
Rudi A. J. O. Dierckx
Index 763
Püsilink: https://www.kriso.ee/db/9789814317740_pe.html